Adjuvant Capital
Overview
Adjuvant Capital is a life sciences venture capital firm that invests in companies developing technologies for high-burden public health challenges in low- and middle-income countries . It focuses on neglected, high-burden, and emerging infectious diseases, maternal, newborn, and child health challenges, reproductive and sexual health and nutrition .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Minervax | Oct 2023 | Series C | Co-investor |
| ChromaCode | May 2020 | Series C Extension | Lead |
| Excision BioTherapeutics | Feb 2021 | Series A | Co-investor |
| VitriVax, Inc. | Oct 2025 | Series B | Lead |
| Pulmocide | Dec 2022 | Series C Extension | Co-investor |
For institutional investors. Book with your work email.
Key People
Charlie Petty
Co-Founder
Glenn Rockman
Founder and Managing Partner
Gerard Cunningham
Operating Partner
Mark Sullivan AO
Venture Partner
Michael Chang
Venture Partner
Kabeer Aziz
Partner
Abrar Haque
Investor
Giulia Balconi
Life Sciences Venture Capital
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Adjuvant Capital based?
Adjuvant Capital is headquartered in New York City, New York, United States.
When was Adjuvant Capital founded?
Adjuvant Capital was founded in 2018.
How many portfolio companies does Adjuvant Capital have?
Adjuvant Capital has 16 portfolio companies in Caplight's dataset.
What are some companies in Adjuvant Capital's portfolio?
Portfolio companies visible on Caplight include Minervax, ChromaCode, Excision BioTherapeutics, VitriVax, Inc., Pulmocide.
What was Adjuvant Capital's most recent investment shown here?
Adjuvant Capital's most recent investment in this portfolio sample was in VitriVax, Inc. in 2025.
What sectors does Adjuvant Capital focus on?
Adjuvant Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Adjuvant Capital focus on?
Adjuvant Capital typically invests at the Mid stage.
What is Adjuvant Capital's AUM?
Adjuvant Capital's assets under management are estimated between $250.0M and $500.0M.